1. COVID-19 and β-thalassemia: in lieu of evidence and vague nexus

   • Hayder M. Al-Kuraishy
   • Mohamed H. Mazhar Ashour
   • Gaber El-Saber Batiha

   Review Article 05 July 2023 Pages: 1423 - 1433

   

2. Epigenetic alterations and advancement of lymphoma treatment

   • Shuhui Zhuang
   • Zhaobo Yang
   • Fengyuan Che

   Review Article 15 August 2023 Pages: 1435 - 1454

   

3. Non-coding RNAs in leukemia drug resistance: new perspectives on molecular mechanisms and signaling pathways

   • Atefe Rahmati
   • Alireza Mafi
   • Amirhossein Sahebkar

   Review Article 01 August 2023 Pages: 1455 - 1482

   

4. Posttransplant cyclophosphamide beyond haploidentical transplantation

   • Leonardo Javier Arcuri
   • Andreza Alice Feitosa Ribeiro
   • Mariana Nassif Kerbauy

   Review Article 01 June 2023 Pages: 1483 - 1491

5. Non-viral and viral delivery systems for hemophilia A therapy: recent development and prospects

   • Ali Rajabi Zangi
   • Ala Amiri
   • Yousef Javadzadeh

   Review Article 11 November 2023 Pages: 1493 - 1511

   

6. Optimization of cardiovascular risk factor management in patients with BCR::ABL1 negative chronic myeloproliferative neoplasms, current knowledge, and perspectives

   • Ivan Krecak
   • Srdan Verstovsek
   • Marko Lucijanic

   Review Article 04 September 2023 Pages: 1513 - 1523

   

7. Spanish registry of hemoglobinopathies and rare anemias (REHem-AR): demographics, complications, and management of patients with β-thalassemia

   • Eduardo J. Bardón-Cancho
   • José Manuel Marco-Sánchez
   • Elena Cela

   Original Article Open access 23 March 2024 Pages: 1525 - 1539

   

8. Secondary hemophagocytic lymphohistiocytosis in pediatric patients with visceral leishmaniasis and Epstein-Barr virus infection

   • Yuanfang Li
   • Sanjing Li
   • Dao Wang

   Original Article 12 March 2024 Pages: 1541 - 1547

   

9. The evolution of preexisting primary immune thrombocytopenia after COVID-19 onset: A nationally representative, prospective, multicentre, observational study

   • Haixia Fu
   • Xuan Cai
   • on behalf of the Collaborative ITP Working Group

   Research 25 March 2024 Pages: 1549 - 1559

   

10. Late relapse of chronic myeloid leukemia after allogeneic bone marrow transplantation points to KANSARL (KANSL1::ARL17A) alteration: a case report with insights on the molecular landscape

    • Diletta Fontana
    • Giovanni Paolo Maria Zambrotta
    • Carlo Gambacorti-Passerini

    Original Article Open access 07 February 2024 Pages: 1561 - 1568

    

11. Spotlight on the real-world treatment of CML pts in Germany: a retrospective survey in private oncology practices

    • Georg-Nikolaus Franke
    • Gunnar Loewe
    • Kathleen Jentsch-Ullrich

    Original Article Open access 12 March 2024 Pages: 1569 - 1575

    

12. The influence of hospital volume and physician volume on early mortality in acute promyelocytic leukemia patients

    • Chia-Ying Wu
    • Chiu-Mei Yeh
    • Chia-Jen Liu

    Original Article Open access 26 March 2024 Pages: 1577 - 1586

    

13. Diagnostic management of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in close interaction with therapeutic considerations

    • Evgenii Shumilov
    • Paolo Mazzeo
    • Ulrike Bacher

    Original Article Open access 09 January 2024 Pages: 1587 - 1599

    

14. Efficacy of prophylactic antibiotics for the prevention of neutropenic fever in patients with multiple myeloma receiving high-dose cyclophosphamide for stem cell mobilization

    • Li-qiong Hou
    • Jun-Ru Liu
    • Juan Li

    Original Article Open access 25 January 2024 Pages: 1601 - 1611

    

15. Conditional survival to assess prognosis in patients with chronic lymphocytic leukemia

    • Pascal Schlosser
    • Annett Schiwitza
    • Rainer Claus

    Original Article Open access 03 February 2024 Pages: 1613 - 1622

    

16. How to improve RCHOP as frontline therapy for diffuse large B-cell lymphoma: a systematic review and meta-analysis of 21 randomized controlled trials

    • Stergios Intzes
    • Marianthi Symeonidou
    • Emmanouil Spanoudakis

    Original Article 08 January 2024 Pages: 1623 - 1633

    

17. Venetoclax plus dose-adjusted R-EPOCH (VR-DA-EPOCH) or G-EPOCH bridging to subsequent cellular therapy for the patients with transformed lymphoma a single center clinical experience

    • Shuchao Qin
    • Rui Jiang
    • Huayuan Zhu

    Original Article Open access 22 January 2024 Pages: 1635 - 1642

    

18. Immunotyping of peripheral blood lymphocytes by flow cytometry reveals Th cell as a potential prognostic biomarker for extranodal NK/T-cell lymphoma

    • Fei Qi
    • Yuce Wei
    • Jun Zhu

    Original Article 09 January 2024 Pages: 1643 - 1653

    

19. Prediction of severe infections in chronic lymphocytic leukemia: a simple risk score to stratify patients at diagnosis

    • Roberta Murru
    • Andrea Galitzia
    • Giovanni Caocci

    Original Article Open access 18 January 2024 Pages: 1655 - 1664

    

20. Development of a whole spinal MRI-based tumor burden scoring method in participants with multiple myeloma: a pilot study of prognostic significance

    • Sha Cui
    • Yinnan Guo
    • Jinliang Niu

    Original Article 07 February 2024 Pages: 1665 - 1673

    

21. Cause-specific mortality in a population-level cohort of diffuse large B-cell lymphoma following chemotherapy in the early 21st century

    • Li-Ye Bei
    • Chun-Yu Shang
    • Wei Xu

    Original Article 16 January 2024 Pages: 1675 - 1685

    

22. Epidemiological features and a survival nomogram for primary lymphoma of the male genital tract

    • Rongli Xie
    • Zekai Mao
    • Tiantian Sun

    Original Article 01 March 2024 Pages: 1687 - 1695

    

23. Herombopag for the treatment of persistent thrombocytopenia following hematopoietic stem cell transplantation

    • Miao Zhou
    • Tongyu Li
    • Guifang Ouyang

    Original Article 27 March 2024 Pages: 1697 - 1704

    

24. Autotaxin is a potential predictive marker for the development of veno-occlusive disease/sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation

    • Kazuya Takemura
    • Mika Nakamae
    • Hirohisa Nakamae

    Original Article 18 March 2024 Pages: 1705 - 1715

    

25. Allogeneic stem cell transplantation and CAR-T in B-cell Non-Hodgkin Lymphoma: a two-center experience and review of the literature

    • Santiago Mercadal
    • Alberto Mussetti
    • Daniel R. Couriel

    Original Article 02 March 2024 Pages: 1717 - 1727

    

26. Comparison of rabbit ATLG and ATG for GVHD prophylaxis in hematological malignancies with haploidentical hematopoietic stem cell transplantation

    • Zhengqin Tian
    • Qihang Man
    • Jingbo Wang

    Research 28 March 2024 Pages: 1729 - 1736

    

27. Impact of BK polyomavirus viremia on the outcomes of allogeneic hematopoietic stem cell transplantation

    • Yoshihiro Umezawa
    • Kota Yoshifuji
    • Takehiko Mori

    Research 21 March 2024 Pages: 1737 - 1744

    

28. Validation of a Stenotrophomonas maltophilia bloodstream infection prediction score in the hematologic malignancy population

    • Emily L. Gill
    • Christian M. Gill
    • Colleen McEvoy

    Research Open access 08 March 2024 Pages: 1745 - 1752

    

29. Palliative care for patients with hematologic malignancies in Germany: a nationwide survey on everyday practice and influencing factors from the perspective of treating physicians

    • Cordula Gebel
    • Isabel Kruschel
    • Ulrich Wedding

    Research Open access 28 March 2024 Pages: 1753 - 1763

    

30. Adult type I Gaucher disease with splenectomy caused by a compound heterozygous GBA1 mutation in a Chinese patient: a case report

    • Jian-hui Zhang
    • Hui Chen
    • Hong Li

    Case Report 20 March 2024 Pages: 1765 - 1774

    

31. Gilteritinib combined with venetoclax and azacitidine for relapsed acute myeloid leukemia cocurrent with pure red cell aplasia after allogeneic hematopoietic stem cell transplantation: a case report

    • Jiawen Wang
    • Han Zhu
    • Kourong Miao

    Case Report 01 April 2024 Pages: 1775 - 1777

32. Effective treatment of pleural effusion in chronic lymphocytic leukemia with acalabrutinib: a case report

    • Shuhei Kurosawa
    • Takako Yokota
    • Tomonori Nakazato

    Correspondence 21 March 2024 Pages: 1779 - 1781

    

33. The impact of statin use on disease-related symptoms in patients with chronic myeloproliferative neoplasms

    • Hrvoje Holik
    • Marko Lucijanić
    • Ivan Krečak

    Correspondence 13 March 2024 Pages: 1783 - 1785

    

34. Very long-term efficacy of venetoclax combined with hypomethylating agents in two AML elderly: is it the time for treatment discontinuation strategies?

    • Pasquale Niscola
    • Valentina Gianfelici
    • Paolo de Fabritiis

    Correspondence 09 March 2024 Pages: 1787 - 1788

35. Concomitant large deletion and de novo duplication of factor VIII gene in an Indian patient with severe Hemophilia A

    • Debadrita Ray
    • Ritika Sharma
    • Reena Das

    Correspondence 17 February 2024 Pages: 1789 - 1790

    

36. Is eryptosis druggable?

    • Anton Tkachenko

    Editorial 21 March 2024 Pages: 1791 - 1792

37. Loeys-Dietz syndrome with concomitant aplastic anemia

    • Qiang Zha
    • Yu Shi
    • Wenyi Shen

    Letter to the Editor 02 February 2024 Pages: 1793 - 1795

    

38. Progression of myeloproliferative neoplasm with BCR::JAK2 fusion to acute leukemia of ambiguous lineage

    • Edwin Uriel Suárez
    • Miguel Ángel Piris
    • Pilar Llamas

    Letter to the Editor 03 February 2024 Pages: 1797 - 1799

39. Correction to: Identification of a novel fusion gene, RARA::ANKRD34C, in acute promyelocytic leukemia

    • Yue Chen
    • Mengge Pan
    • Peipei Xu

    Correction 27 March 2024 Pages: 1801 - 1801

40. Correction to: Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patientreported outcomes from the CARDINAL study

    • Alexander Röth
    • Wilma Barcellini
    • Ilene C. Weitz

    Correction Open access 23 March 2024 Pages: 1803 - 1803